Dr. Golding is a physician/scientist who has received medical training in Internal Medicine and Rheumatology, and research training in Immunology at the NIH. He has been working as a research/regulator at the FDA since 1985 and is currently the Director of the Division of Plasma-derived Protein Therapeutics in the Office of Therapeutics and Advanced Therapies. Basil does research in Virology, Cell Biology and Immunology. Their most recent publication is “Modulating immunogenicity of Factor IX by fusion to an immunoglobulin Fc domain: a study using hemophilia B mouse model.”
His regulatory responsibilities involve products used to treat genetic deficiency diseases. These products include plasma-derived and recombinant proteins, and gene therapy.
Current Institution:
U.S. Food and Drug Administration,
Center for Biologics Evaluation and Research,
Office of Therapeutics and Advanced Therapies,
Division of Plasma Protein Therapeutics,
Silver Spring, Maryland